PBAC's latest decision on Alefacept: Not recommended (2005). Considered for treatment of severe chronic plaque psoriasis in adult patients who have a Psoriasis Area and Severity Index (PASI) score ≥15 and are refractory, intolerant or contraindicated to currently available therapies.
PBAC outcome
Not recommended
2005
ICER (AUD/QALY)
$75k/QALY
Range: $45k/QALY–$75k/QALY
Submissions
1
first 2005
Submissions
1
2005 → 2005
Eligible population
adult patients with severe chronic plaque psoriasis who have a Psoriasis Area and Severity Index (PASI) score ≥15 and are refractory, intolerant or contraindicated to currently available therapies
Therapy area
Dermatology
Evidence base
RCT
Primary endpoint
ORR
Key trials
C99-711, C99-712
Comparator
placebo
Economic model
CUA
Why PBAC said no
Reasons cited in the latest PSD: unacceptable and uncertain cost-effectiveness, base-case ICER judged unacceptably high with series of assumptions favouring alefacept, model omitted re-initiation of treatment allowing more realistic ICER to be higher and less acceptable, base case ratio numerically higher than best-case scenario from previous submission